Palisade Bio Stock Update
Palisade Bio (ticker: PALI) closed the trading session on Wednesday, 21 May 2026, at a price of USD 1.43 per share, representing a decline of 4.96 % from the previous close. The 24‑hour trading volume for the company was approximately USD 2.5 million.
Market Metrics
- Market Capitalization: USD 245.7 million
- Shares Outstanding: 174.3 million
- Simple Moving Average (200 days): USD 1.88
- 52‑Week High: USD 2.86 (recorded on 22 April 2026)
- 52‑Week Low: USD 1.32 (recorded on 19 October 2026)
Since the end of the previous month, Palisade Bio’s share price has fallen by 20.71 %.
Related Stock Performance (Last 24 Hours)
| Company | Ticker | Price Change | Current Price | Market Capitalization |
|---|---|---|---|---|
| Seaport Entertainment | SEG | -2.42 % | USD 22.55 | USD 291.7 million |
| Blue Acquisition | BACC | +0.10 % | USD 10.43 | USD 291.4 million |
| M‑tron Industries | MPTI | +1.79 % | USD 67.75 | USD 293.8 million |
| Launchpad Cadenza Acquisition | LPCV | 0 % | USD 10.13 | USD 291.2 million |
| Arcturus Therapeutics Holding | ARCT | +0.77 % | USD 10.98 | USD 293.9 million |
Launchpad Cadenza Acquisition has a price‑to‑earnings ratio of 309.88.
Company Overview
Palisade Bio, Inc. is a biopharmaceutical company headquartered in Carlsbad, United States. The company focuses on the development of therapies for patients experiencing acute and chronic gastrointestinal complications resulting from post‑operative digestive enzyme damage. Palisade Bio operates globally within the biotechnology and healthcare sectors and is listed on the Nasdaq stock exchange. Further information can be found on its website at www.palisadebio.com .
